Rydex S&P MidCap 400 Pure Growth Fund Class A (RYMGX)

55.32
Net Asset Value
-0.90%
1 Day
+2.52%
Year-to-Date
Overall Morningstar Rating
Mid-cap growth
Style or Category
4.75
Sales Expenses
1.52%
Expense Ratio
Above Average
Morningstar Risk Rating™
Investment Objective The investment seeks investment results that match- before fees and expenses- the performance of the S&P MidCap 400 Pure Growth Index for mid-cap growth securities on a daily basis. The fund employs as its investment strategy a program of investing in the common stock of companies that are within the capitalization range of the underlying index and derivative instruments. It will invest at least 80% of its net assets- plus any borrowings for investment purposes- in securities of companies in the underlying index and derivatives and other instruments whose performance is expected to correspond to that of the underlying index. The fund is non-diversified.

Performance

1 month-2.59% 3 years+5.29%
3 months-4.17% 5 years+9.64%
1 year+15.21% Since inception+9.93%
Data through --

Peer Comparisonvs. Mid-cap growth

 RYMGXCategory
Performance 5-yr return+9.64%+11.94%
Expense ratio1.52%1.21%
Risk 5 year sharpe ratio0.721.00
Net assets$99.3M$1.6B
Average market cap$5.6B$11.9B
Average P/E27.924.9
Portfolio turnover127%127%

There are thousands of mutual funds to choose from. Get Money Magazine’s picks in all major categories.

Fund Management and Purchase Info

Fund familyRydex Funds
Fund manager & tenureMichael Byrum / 14 Years
Minimal initial investment$2,500.00
Minimum IRA investment$1,000.00

Holdings

U.S. stock97.91%
International stock1.63%
Cash1.05%
Fixed income0.00%
Other0.00%
Top 5 Sectors
Portfolio weighting
Consumer service 19.36%
Healthcare 13.98%
Consumer goods 13.07%
Industrial materials 10.82%
Hardware 6.58%
Top 10 Holdings
Portfolio weighting
ABMD Abiomed Inc2.69%
MKSI MKS Instruments Inc2.06%
LPX Louisiana-Pacific Corp1.85%
TREE LendingTree Inc1.82%
FTNT Fortinet Inc1.79%
JBL Jabil Inc1.75%
MSCI MSCI Inc1.72%
SKX Skechers USA Inc1.72%
MDSO Medidata Solutions Inc1.66%
LIVN LivaNova PLC1.63%